| Barchart Demo Center |
$5.70
+0.61 (+11.98%)
as of May 31, 2024
as of May 31, 2024
| Profile | |
|---|---|
| Ticker Symbol | EBS |
| Exchange | NYSE |
| Contact Information |
300 Professional Drive GAITHERSBURG, MD USA P: 240-631-3200 |
| CEO/President | Joseph C. Papa |
| Earnings at a Glance | ||||
|---|---|---|---|---|
| Earnings | 03/31/24 0.17 |
12/31/23 -0.91 |
09/30/23 -5.08 |
06/30/23 -5.15 |
| Price Earnings Ratio | N/A | |||
| EPS Growth | 68.22 | |||
| Most Recent Earnings ($) | 0.17 | |||
| Annual EPS ($) | -11.01 | |||
| Business Summary | |
|---|---|
| Emergent BioSolutions Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate AV7909 to the U.S. government. It supplies smallpox vaccine ACAM2000 botulism therapeutic BAT anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray ACAM2000 raxibacumab Vaxchora and Vivoti through several acquisitions. | |
| Industry/Sector | SIC-2834 Pharmaceutical Preparations Medical - Biomedical Indices Russell 3000 Indices Russell 2000 |